Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | STAT1 | P42224 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21322119 | 0.84 | GRM5 (0.60) | NPC1TDP1TEAD3GRM5TSHR | |
| SCHEMBL21430557 | 0.81 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2HPGDTDP1 | |
| SCHEMBL4830376 | 0.80 | GRM5 (0.71) | NPC1SMN1; SMN2TDP1ALDH1A1KMT2A | |
| SCHEMBL8599293 | 0.80 | NPC1 (0.81) | NPC1RAB9ASMN1; SMN2HPGDTDP1 | |
| SCHEMBL22875110 | 0.79 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2HPGDTEAD3 | |
| SCHEMBL13315137 | 0.78 | GRM5 (0.73) | NPC1SMN1; SMN2TDP1ALDH1A1KMT2A | |
| SCHEMBL10371234 | 0.78 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2HPGDTDP1 | |
| SCHEMBL291194 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2TEAD3ALDH1A1HTTTSHR | |
| SCHEMBL7376148 | 0.77 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2HPGDTDP1 | |
| SCHEMBL19423249 | 0.77 | NAAA (0.68) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187435-B2 | Bridged Spiro[2.4]heptane ester derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-11-17 | — | — | US | disclosed |
| EP-2640699-B1 | BRIDGED SPIRO[2,4]HEPTANE ESTER DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-10-07 | — | — | EP | disclosed |
| EP-2640699-A2 | BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-05 | — | — | US | disclosed |
| WO-2012066488-A2 | BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ADH1A, ADH1C, NAPA | NPC1 3070/4885RAB9A 3923/4885SMN1; SMN2 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.